Medpace Holdings, Inc. (MEDP)
MEDPNASDAQ-GSBiotechnology: Commercial Physical & Biological Resarch
$664.54
-8.39 (-1.25%) today
At the close, Nov 10, 4:00 PM ET. After hours $665.00 +0.07%
- Market cap
- $18.59bn
- P/E
- 36.8
- EPS, last 4 quarters
- $18.04
- Dividend yield
- –
- Day range
- $661.41 to $671.92
- 52-week range
- $373.00 to $693.97
- Average volume
- 275.6k
- Previous close
- $672.93
Analysts
9 coveringHold3 buy, 6 hold, 0 sell
Targets a year out average $670.22, +0.9% from here
Earnings
next estimate $4.82Next report
Dec 2025
+11.7%
Mar 2026
+14.4%
Jun 2026
+4.2%
Sep 2026
+8.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $708.45m | $706.60m | $707.33m | $716.00m |
| Gross profit | $205.32m | $196.33m | $201.64m | $223.88m |
| Operating income | $153.27m | $141.50m | $146.82m | $165.54m |
| Net income | $135.13m | $123.87m | $121.36m | $137.46m |
Last four quarters: revenue $2.84bn, margin 18.2%, free cash flow $667.63m
News
8 latest- TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances Zacks · 1 day ago
- NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View UpZacks · 1 day ago
- Mettler-Toledo Stock Up on Q3 Earnings & Revenue Beat, '26 View UpZacks · 4 days ago
- If You Invested $1000 in Medpace a Decade Ago, This is How Much It'd Be Worth NowZacks · 4 days ago
- STE Stock Up on Q2 Earnings & Revenue Beat, '27 EPS View UpZacks · 5 days ago
- Edwards Q3 Earnings & Revenues Surpass Estimates, Stock ClimbsZacks · 5 days ago
- CVS Q3 Earnings & Revenues Top Estimates, Stock Up in Pre-MarketZacks · 6 days ago
- Charles River Q3 Earnings & Revenues Top Estimates, Stock RisesZacks · 6 days ago
The company
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,600 people across 46 countries as of September 30, 2026.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- medpace.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.